Navigation Links
Soligenix Announces Publication of Positive Stability Results with RiVax(TM), its Vaccine Against Ricin Toxin
Date:2/2/2010

4; is currently the subject of a confirmatory Phase 3 clinical trial for the treatment of acute GI GVHD and an NIH-supported, Phase 2, randomized, double-blind, placebo-controlled trial in the prevention of acute GVHD. Both of these trials are actively enrolling patients. Soligenix has also recently initiated an NIH-supported Phase 1/2 clinical trial of SGX201 in the prevention of acute radiation enteritis. Additionally, Soligenix has a Lipid Polymer Micelle (LPM™) drug delivery technology for the oral delivery of leuprolide for the treatment of prostate cancer and endometriosis.

Through its Biodefense Division, Soligenix is developing biomedical countermeasures pursuant to the Project BioShield Act of 2004. Soligenix's lead biodefense product in development is a recombinant subunit vaccine called RiVax™, which is designed to protect against the lethal effects of exposure to ricin toxin. RiVax™ has been shown to be well tolerated and immunogenic in a Phase 1 clinical trial in normal volunteers. RiVax™ will also be the subject of a recent $9.4 million NIH grant received by the Company supporting development of new heat stable vaccines.

For further information regarding Soligenix, Inc., please visit the Company's website at www.soligenix.com.

This press release contains forward-looking statements that reflect Soligenix, Inc.'s current expectations about its future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes," "intends," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual eve
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Soligenix Announces Publication of Positive Pre-Clinical Results with RiVax(TM), Its Vaccine Against Ricin Toxin
2. Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
3. Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines
4. ISTA Pharmaceuticals Announces Preliminary, Unaudited Revenue of $110.6 Million in 2009
5. CareFusion Announces 5-Year, Sole Source Pyxis(R) Perioperative Solutions Agreement With CHRISTUS Health
6. BIA Announces Release of Solis(TM) Integrated ESI Management and E-Discovery Platform
7. Pioneer(R) Surgical Technology, Inc. Announces New Expansion Plan
8. Cardica Announces Fiscal 2010 Second Quarter Financial Results
9. Sequenom Announces Addition to Clinical Advisory Board
10. Omnicell Announces Fourth Quarter and Full-Year 2009 Results
11. Life Spine(R) Announces FDA Clearance of DYNA-LINK(R) Spinal System and PRESIDIO(TM) Spinal Plating System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... NEWPORT NEWS, Va. , Aug. 3, 2015 ... will be joining Orthopaedic & Spine Center ... help them to manage their chronic pain through ... Dr. Robinson is a Fellowship-trained, certified medical ... and pain medicine. His vast experience ranges from ...
(Date:8/3/2015)... SINGAPORE , Aug. 3, 2015 ... Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a ... today announced financial results for its first fiscal ... Quarter Highlights and Recent Developments: ... progress in improving its cost structure, driven by ...
(Date:8/3/2015)... , Aug. 3, 2015 Merrimack Pharmaceuticals, Inc. (Nasdaq: ... host its Second Quarter 2015 Investor Conference Call and ... The call will cover an update on ... quarter 2015 financials. A press release detailing the information ... the afternoon of Monday, August 10. Investors and the ...
Breaking Medicine Technology:Orthopaedic & Spine Center Introduces New Pain Psychologist 2Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 2Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 3Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 4Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 5Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 6Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call 2
... BELGRADE, Mont., July 26, 2011 Bacterin ... a leader in the development of revolutionary bone graft material ... call on Thursday, August 11, at 4:30 p.m. Eastern time ... 2011. Financial results will be issued in a press release ...
... America, Inc. today announced plans to debut expanded software ... EasyCell® assistant Automated Cell Imaging Analyzer during ... Conference and Clinical Lab Expo July 24 - 28 ... hematology portfolio can be seen at Sysmex,s exhibit booth, ...
Cached Medicine Technology:Bacterin Sets Second Quarter 2011 Conference Call for Thursday, August 11, 2011 at 4:30 p.m. ET 2Sysmex America to Debut Expanded Software Products for Middleware and Cell Image Analysis at AACC 2011 2
(Date:8/3/2015)... ... August 03, 2015 , ... ... development of it’s new program “Designing Secure Healthcare Systems” This three-day, highly ... technology leaders from healthcare organizations with access to the tactics, techniques and practices ...
(Date:8/3/2015)... ... ... The U.S. Food and Drug Administration (FDA) recently approved a new non-invasive ... occurs naturally in the body and helps absorb and breakdown fat cells. Previously, plastic ... These are invasive procedures and very expensive for most people. Now with Kybella, there ...
(Date:8/3/2015)... ... August 03, 2015 , ... A July 13 article from ... Cells Found to Release Natural Painkiller That Can Last 'For Five Weeks'" discusses ... the report, the new study showed that harvesting stem cell-rich bone marrow from the ...
(Date:8/3/2015)... , ... August 03, 2015 , ... Illinois Health & ... July 31. , The acquisition includes all of IBAM NA’s cyclotron sites and ... have both, a robust regionally located business, as well as a large manufacturing hub ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... firm, announced today that Joe Williams has joined its growing California employee benefits ... HUB's differentiated service model to his clients. Mr. Williams will be joining the ...
Breaking Medicine News(10 mins):Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2
... DENVER, June 24 The National Sports Center for the Disabled and American ... Classic from Friday, July 17th to Sunday, July 19th at the Winter Park ... with a wide variety of well-marked trails for all levels of riders and ... , World Class Mountain Biking! , ...
... researchers say , , WEDNESDAY, June 24 (HealthDay ... well in an early clinical trial against breast, ovarian ... to developing these malignancies. , Women who carry BRCA1 ... and ovarian cancer, and among men these mutations are ...
... 24 Validation and Compliance Institute (VCI), which provides ... industries, will offer a series of Dietary Supplement Good ... division of NSF International. , , ... GMP regulations for dietary supplements, which the US Food ...
... 24 Speaker Nancy Pelosi held a brief a press availability ... , Jim Douglas of Vermont , and Chris Gregoire ... to discuss health care reform. Below are their remarks: ... indeed to welcome three very distinguished governors to The Speaker,s Office - ...
... , ROCHESTER, Minn., June 24 The Mayo Clinic ... collaborative symposium on innovations in health care experience and ... open to the public. It will feature nationally recognized ... in health care delivery models, including Web-based tools. The ...
... biomarkers in patients with only mild memory problems , ... disease can be detected in the cerebrospinal fluid in ... study suggests. , University of Gothenburg researchers analyzed cerebrospinal ... typical pattern of biomarkers known as the "CSF AD ...
Cached Medicine News:Health News:18th Annual Fat Tire Classic Benefiting the National Sports Center for the Disabled & the American Red Cross Mile High July 17th - 19th, 2009 2Health News:New Cancer Drug Fights Tumors in Those With BRCA Mutations 2Health News:New Cancer Drug Fights Tumors in Those With BRCA Mutations 3Health News:Validation & Compliance Institute, LLC, to Provide Dietary Supplement GMP Training for NSF International 2Health News:Pelosi, Governors' Remarks Before Meeting on Health Care 2Health News:Pelosi, Governors' Remarks Before Meeting on Health Care 3Health News:Pelosi, Governors' Remarks Before Meeting on Health Care 4Health News:Mayo Clinic Center for Innovation to Sponsor a Collaborative Symposium on Innovations in Health Care Experience and Delivery 2Health News:Mayo Clinic Center for Innovation to Sponsor a Collaborative Symposium on Innovations in Health Care Experience and Delivery 3Health News:Clues to Alzheimer's Spotted Earlier in Disease 2
For the quantitative determination of Iron and IBC in serum. Colorimetric method utilizing ferrozine. Endpoint procedure measured at 560 nm. Linearity: 500 ug/dl....
HDL Cholesterol (PEG) Precip. Reagent + 5 ml of 50 mg/dl cholesterol std....
Intended for the quantitative in vitro enzymatic determination of JDL-Cholesterol in human serum or plasma. Two point reaction. Wavelength: 600 nm. Linearity: 1 to 150 mg/dL (0.03 mmol/L to 3.89 mmol...
... Intended for the quantitative ... plasma. Two vials, dry ... alphaketoglutarate. Uses NADPH to ... plasma compounds. Reaction: Enzymatic, ...
Medicine Products: